Ad Astra Diagnostics, Inc.
Ad Astra Diagnostics (AAD) is developing patient-side, rapid diagnostic systems for faster health decisions. Their flagship product, QScout CBC, provides a complete blood count in about 2 minutes from a fingerstick or venous blood sample, eliminating the need to wait for central lab results. QScout CBC also measures immature granulocytes, an early marker for sepsis. The QScout RLD is the first cleared test for measuring immature granulocytes at the point of care. The company emphasizes its technology uses an imaging-based system with AI analysis, avoiding the challenges of flow cytometry or the Coulter Principle. AAD aims to increase access to diagnostics and improve patient care by enabling fast health decisions.
Ad Astra Diagnostics, Inc.
Ad Astra Diagnostics (AAD) is developing patient-side, rapid diagnostic systems for faster health decisions. Their flagship product, QScout CBC, provides a complete blood count in about 2 minutes from a fingerstick or venous blood sample, eliminating the need to wait for central lab results. QScout CBC also measures immature granulocytes, an early marker for sepsis. The QScout RLD is the first cleared test for measuring immature granulocytes at the point of care. The company emphasizes its technology uses an imaging-based system with AI analysis, avoiding the challenges of flow cytometry or the Coulter Principle. AAD aims to increase access to diagnostics and improve patient care by enabling fast health decisions.